SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-017596
Filing Date
2023-11-03
Accepted
2023-11-03 16:15:16
Documents
13
Period of Report
2023-11-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K adap-20231101x8k.htm   iXBRL 8-K 30580
  Complete submission text file 0001558370-23-017596.txt   242890

Data Files

Seq Description Document Type Size
2 EX-101.SCH adap-20231101.xsd EX-101.SCH 3797
3 EX-101.LAB adap-20231101_lab.xml EX-101.LAB 1358
4 EX-101.PRE adap-20231101_pre.xml EX-101.PRE 11138
7 EXTRACTED XBRL INSTANCE DOCUMENT adap-20231101x8k_htm.xml XML 4916
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 231376505
SIC: 2836 Biological Products, (No Diagnostic Substances)